Drug Profile
Respiratory syncytial virus vaccine - Pfizer
Alternative Names: ABRYSVO; PF-06928316; PF-6928316; Respiratory syncytial virus (RSV) prefusion F subunit vaccine - Pfizer; RSV Vaccine - Pfizer; RSVpreF - PfizerLatest Information Update: 15 Apr 2024
Price :
$50
*
At a glance
- Originator Pfizer
- Class Respiratory syncytial virus vaccines; Subunit vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Respiratory syncytial virus infections
Most Recent Events
- 09 Apr 2024 Immunogenicity and adverse event data from the phase III MONeT trial released by Pfizer
- 26 Mar 2024 Registered for Respiratory syncytial virus infections (In the elderly, Prevention, In adults) in Japan (IM)
- 20 Mar 2024 Registered for Respiratory syncytial virus infections (In infants, In neonates, Prevention) in Australia (IM)